| Drug− disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity F Sanaee, JD Clements, AWG Waugh, RN Fedorak, R Lewanczuk, ... British journal of clinical pharmacology 72 (5), 787-797, 2011 | 37 | 2011 |
| Decoration of anti-CD38 on nanoparticles carrying a STAT3 inhibitor can improve the therapeutic efficacy against myeloma YH Huang, MR Vakili, O Molavi, Y Morrissey, C Wu, I Paiva, AH Soleimani, ... Cancers 11 (2), 248, 2019 | 31 | 2019 |
| NSAIDs do not require the presence of a carboxylic acid to exert their anti-inflammatory effect–why do we keep using it? N Ullah, Z Huang, F Sanaee, A Rodriguez-Dimitrescu, F Aldawsari, ... Journal of enzyme inhibition and medicinal chemistry 31 (6), 1018-1028, 2016 | 29 | 2016 |
| Development and pharmacokinetic evaluation of a self-nanoemulsifying drug delivery system for the oral delivery of cannabidiol LY Kok, P Bannigan, F Sanaee, JC Evans, M Dunne, M Regenold, ... European Journal of Pharmaceutical Sciences 168, 106058, 2022 | 23 | 2022 |
| A synthetically lethal nanomedicine delivering novel inhibitors of polynucleotide kinase 3′-phosphatase (PNKP) for targeted therapy of PTEN-deficient colorectal cancer SMA Sadat, IM Paiva, Z Shire, F Sanaee, TDR Morgan, M Paladino, ... Journal of Controlled Release 334, 335-352, 2021 | 12 | 2021 |
| Pharmacokinetics of nebivolol in the rat: low oral absorption, loss in the gut and systemic stereoselectivity F Sanaee, D Valente Neves, VL Lanchote, F Jamali Biopharmaceutics & drug disposition 34 (6), 312-320, 2013 | 11 | 2013 |
| Action and disposition of the β3-agonist nebivolol in the presence of inflammation; an alternative to conventional β1-blockers F Sanaee, F Jamali Current Pharmaceutical Design 20 (9), 1311-1317, 2014 | 6 | 2014 |
| Nano-delivery of a novel inhibitor of polynucleotide kinase/phosphatase (PNKP) for targeted sensitization of colorectal cancer to radiation-induced DNA damage SMA Sadat, M Wuest, IM Paiva, S Munira, N Sarrami, F Sanaee, X Yang, ... Frontiers in Oncology 11, 772920, 2021 | 5 | 2021 |
| Design and evaluation of albumin nanoparticles for the delivery of a novel β-tubulin polymerization inhibitor A Spada, J Emami, F Sanaee, M Aminpour, MP Igor, J Tuszynski, ... Journal of Pharmacy & Pharmaceutical Sciences 24, 344-362, 2021 | 5 | 2021 |
| Assessing the physicochemical stability of a compounded neonatal trace element solution F Sanaee, T Mysak, L Sanderson, T Donaldson, MR Vakili, A Lavasanifar Journal of Pharmacy & Pharmaceutical Sciences 21 (1s), 103s-116s, 2018 | 2 | 2018 |
| Effects of Inflammation and the Severity of Disease on the Action and Disposition of Drugs F Sanaee University of Alberta (Canada), 2014 | 1 | 2014 |
| Abstract P2103: Cannabidiol Protects Cardiac Function In Vivo And Inhibits Endothelial-to-mesenchymal Transition In Vitro: A Potential Anti-fibrotic Therapy For … MK Krishnamoorthi, F Sanaee, A Lavasanifar, K Youker, A Bhimaraj Circulation Research 131 (Suppl_1), AP2103-AP2103, 2022 | | 2022 |
| Cannabidiol Loaded Nanoparticles Exhibit an Anti-Fibrotic Effect in a Mouse Model of Non-Ischemic Heart Failure MK Krishnamoorthi, F Sanaee, A Lavasanifar, A Bolton, K Youker, ... Circulation 144 (Suppl_1), A10708-A10708, 2021 | | 2021 |
| DISEASE-DRUG INTERACTION: REDUCES RESPONSE TO CALCIUM CHANNEL BLOCKER VERAPAMIL DESPITE INCREASED CONCENTRATION IN ACTIVE CROHN'S DISEASE F Sanaee, JD Clements, A Waugh, R Fedorak, RZ Lewanczuk, F Jamali CANADIAN JOURNAL OF CARDIOLOGY 26, 56D-57D, 2010 | | 2010 |
| DISEASE-DRUG INTERACTION: REDUCES RESPONSE TO VERAPAML DESPITE INCREASED CONCENTRATION IN ACTIVE CROHN'S DISEASE. F Sanaee, JD Clements, A Waugh, R Fedorak, R Lewanczuk, F Jamali JOURNAL OF CLINICAL PHARMACOLOGY 49 (9), 1124-1124, 2009 | | 2009 |
